Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
for
Non Small Cell Lung Cancer (NSCLC)
Location: 1 recruiting location
Sponsor: Integro Theranostics
Sex: All
Age: 18+
Code: NCT07276789
Phase2, Recruiting
Active & ResponsiveNew
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
for
Idiopathic Pulmonary Fibrosis
Location: 1 recruiting location
Sponsor: Contineum Therapeutics
Sex: All
Age: 40+
Code: NCT07284459
Phase2, Recruiting
Active & ResponsiveNew
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
for
Antibody Mediated Rejection of Lung Transplant
Location: 2 recruiting locations
Sponsor: Washington University School of Medicine
Sex: All
Age: 18+
Code: NCT06990711
Phase1, Recruiting
Active & ResponsiveNew
Triple EIT (Electrical Impedance Tomography)
for
Neonates and Preterm Infants, Cardiopulmonary
Location: 1 recruiting location
Sponsor: University of Colorado, Denver
Sex: All
Age: 0 - 25
Code: NCT07247474
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & ResponsiveNew
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
for
Respiratory Syncytial Virus (RSV)
Location: 1 recruiting location
Sponsor: Johns Hopkins University
Sex: All
Age: 18+
Code: NCT07050732
Phase2, Recruiting
Active & ResponsiveNew
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
for
Malignant Neoplasm
Location: 1 recruiting location
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07252739
Phase2, Recruiting
Active & Responsive
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
for
Small-cell Lung Cancer
Location: 1 recruiting location
Sponsor: Emory University
Sex: All
Age: 18+
Code: NCT04342429
Recruiting
Active & Responsive
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: 21 recruiting locations
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT05787587
Phase1, Recruiting
Active & Responsive
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)